[1]
|
Bray, F., Ferlay, J., Soerjomataram, I., et al. (2018) Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 68, 394-424.
https://doi.org/10.3322/caac.21492
|
[2]
|
Siegel, R.L., Miller, K.D. and Jemal, A. (2019) Cancer Statistics, 2019. CA: A Cancer Journal for Clinicians, 69, 7-34. https://doi.org/10.3322/caac.21551
|
[3]
|
American Cancer Society (2016) Cancer Treatment & Survivorship Facts & Figures, 2016-2017. American Cancer Society, Atlanta.
|
[4]
|
Underwood, E.A., et al. (2019) Cognitive Effects of Adjuvant Endocrine Therapy in Older Women Treated for Early-Stage Breast Cancer: A 1-Year Longitudinal Study. Support Care Cancer, 27, 3035-3043. https://doi.org/10.1007/s00520-018-4603-5
|
[5]
|
Bender, C.M., et al. (2007) Memory Impairments with Adjuvant Anastrozole versus Tamoxifen in Women with Early-Stage Breast Cancer. Menopause, 14, 995-998.
https://doi.org/10.1097/gme.0b013e318148b28b
|
[6]
|
Castellon, S.A., Ganz, P.A., Bower, J.E., Petersen, L., Abraham, L. and Greendale, G.A. (2004) Neurocognitive Performance in Breast Cancer Survivors Exposed to Adjuvant Chemotherapy and Tamoxifen. Journal of Clinical and Experimental Neuropsychology, 26, 955-969. https://doi.org/10.1080/13803390490510905
|
[7]
|
Van Dyk, K., Crespi, C.M., Bower, J.E., et al. (2019) The Cognitive Effects of Endocrine Therapy in Survivors of Breast Cancer: A Prospective Longitudinal Study up to 6 Years after Treatment. Cancer, 125, 681-689.
https://doi.org/10.1002/cncr.31858
|
[8]
|
Plas, M., Rotteveel, E., Izaks, G.J., et al. (2017) Cognitive Decline after Major Oncological Surgery in the Elderly. European Journal of Cancer, 86, 394-402.
https://doi.org/10.1016/j.ejca.2017.09.024
|
[9]
|
Kurita, G.P., Sjorgen, P., Ekholm, O., et al. (2011) Prevalence and Predictors of Cognitive Dysfunction in Opioid-Treated Patients with Cancer: A Multinational Study. Journal of Clinical Oncology, 29, 1297-1303.
https://doi.org/10.1200/JCO.2010.32.6884
|
[10]
|
Ahles, T.A., Saykin, A.J., McDonald, B.C., et al. (2008) Cognitive Function in Breast Cancer Patients Prior to Adjuvant Treatment. Breast Cancer Research and Treatment, 110, 143-152. https://doi.org/10.1007/s10549-007-9686-5
|
[11]
|
Wefel, J.S., Lenzi, R., Theriault, R.L., et al. (2004) The Cognitive Sequelae of Standard-Dose Adjuvant Chemotherapy in Women with Breast Carcinoma: Results of a Prospective, Randomized, Longitudinal Trial. Cancer, 100, 2292-2299.
https://doi.org/10.1002/cncr.20272
|
[12]
|
Hermelink, K., Untch, M., Lux, M.P., et al. (2007) Cognitive Function during Neoadjuvant Chemotherapy for Breast Cancer: Results of a Prospective, Multicenter, Longitudinal Study. Cancer, 109, 1905-1913. https://doi.org/10.1002/cncr.22610
|
[13]
|
Menning, S., de Ruiter, M.B., Veltman, D.J., et al. (2015) Multimodal MRI and Cognitive Function in Patients with Breast Cancer Prior to Adjuvant Treatment—The Role of Fatigue. NeuroImage: Clinical, 7, 547-554.
https://doi.org/10.1016/j.nicl.2015.02.005
|
[14]
|
Polsky, D., Doshi, J.A., Marcus, S., et al. (2005) Long-Term Risk for Depressive Symptoms after a Medical Diagnosis. Archives of Internal Medicine, 165, 1260-1266.
https://doi.org/10.1001/archinte.165.11.1260
|
[15]
|
Sotelo, J.L., Musselman, D. and Nemeroff, C. (2014) The Biology of Depression in Cancer and the Relationship between Depression and Cancer Progression. International Review of Psychiatry, 26, 16-30.
https://doi.org/10.3109/09540261.2013.875891
|
[16]
|
MacQueen, G.M. and Memedovich, K.A. (2017) Cognitive Dysfunction in Major Depression and Bipolar Disorder: Assessment and Treatment Options. Psychiatry and Clinical Neurosciences, 71, 18-27. https://doi.org/10.1111/pcn.12463
|
[17]
|
Culpepper, L., Lam, R.W. and McIntyre, R.S. (2017) Cognitive Impairment in Patients with Depression: Awareness, Assessment, and Management. Journal of Clinical Psychiatry, 78, 1383-1394. https://doi.org/10.4088/JCP.tk16043ah5c
|
[18]
|
Hermelink, K., Bühner, M., Sckopke, P., et al. (2017) Chemotherapy and Post- Traumatic Stress in the Causation of Cognitive Dysfunction in Breast Cancer Patients. Journal of the National Cancer Institute, 109.
https://doi.org/10.1093/jnci/djx057
|
[19]
|
Hermelink, K., Voigt, V., Kaste, J., et al. (2015) Elucidating Pretreatment Cognitive Impairment in Breast Cancer Patients: The Impact of Cancer-Related Post-Traumatic Stress. Journal of the National Cancer Institute, 107, PII: djv099.
https://doi.org/10.1093/jnci/djv099
|
[20]
|
Van Damn, F.S., Schagen, S.B., Muller, M.J., et al. (1998) Impairment of Cognitive Function in Women Receiving Adjuvant Treatment for High-Risk Breast Cancer: High-Dose versus Standard-Dose Chemotherapy. Journal of the National Cancer Institute, 90, 210-218. https://doi.org/10.1093/jnci/90.3.210
|
[21]
|
Schagen, S.B., van Dam, F.S., Muller, M.J., et al. (1999) Cognitive Deficits after Postoperative Adjuvant Chemotherapy for Breast Carcinoma. Cancer, 85, 640-650.
https://doi.org/10.1002/(SICI)1097-0142(19990201)85:3<640::AID-CNCR14>3.0.CO;2-G
|
[22]
|
Hurricane Voices Breast Cancer Foundation (2007) Cognitive Deficits Lead to “Loss of Self” among Cancer Patients. Science Daily.
http://www.sciencedaily.com/releases/2007/10/071002131248.htm
|
[23]
|
Edelstein, K.B.L. (2014) Cognitive Dysfunction after Chemotherapy for Breast Cancer. Journal of the International Neuropsychological Society, 20, 351-356.
https://doi.org/10.1017/S1355617714000149
|
[24]
|
Schmidt, J.E., Beckjord, E., Bovbjerg, D.H., et al. (2016) Prevalence of Perceived Cognitive Dysfunction in Survivors of a Wide Range of Cancers: Results from the 2010 LIVESTRONG Survey. Journal of Cancer Survivorship, 10, 302-311.
https://doi.org/10.1007/s11764-015-0476-5
|
[25]
|
Meyers, C.A., Byrne, K.S. and Komaki, R. (1995) Cognitive Deficits in Patients with Small Cell Lung Cancer before and after Chemotherapy. Lung Cancer, 12, 231-235.
|
[26]
|
Downie, F.P., Mar Fan, H.G., Houédé-Tchen, N., et al. (2006) Cognitive Function, Fatigue, and Menopausal Symptoms in Breast Cancer Patients Receiving Adjuvant Chemotherapy: Evaluation with Patient Interview after Formal Assessment. Psychooncology, 15, 921-930. https://doi.org/10.1002/pon.1035
|
[27]
|
Shilling, V.J.V. (2007) Self-Reported Cognitive Problems in Women Receiving Adjuvant Therapy for Breast Cancer. European Journal of Oncology Nursing, 11, 6-15.
https://doi.org/10.1016/j.ejon.2006.02.005
|
[28]
|
Skaali, T., Fossa, S.D., Andersson, S., et al. (2011) Self-Reported Cognitive Problems in Testicular Cancer Patients: Relation to Neuropsychological Performance, Fatigue, and Psychological Distress. Journal of Psychosomatic Research, 70, 403-410.
https://doi.org/10.1016/j.jpsychores.2010.12.004
|
[29]
|
Janelsins, M.C., Heckler, C.E., Peppone, L.J., et al. (2018) Longitudinal Trajectory and Characterization of Cancer-Related Cognitive Impairment in a Nationwide Cohort Study. Journal of Clinical Oncology, 36, 3231-3239.
https://doi.org/10.1200/JCO.2018.78.6624
|
[30]
|
Janelsins, M.C., Heckler, C.E., Peppone, L.J., et al. (2016) Cognitive Complaints in Survivors of Breast Cancer after Chemotherapy Compared with Age-Matched Controls: An Analysis from a Nationwide, Multicenter, Prospective Longitudinal Study. Journal of Clinical Oncology, 35, 506-514.
https://doi.org/10.1200/JCO.2016.68.5826
|
[31]
|
Cleeland, C.S., Mendoza, T.R., Wang, X.S., et al. (2000) Assessing Symptom Distress in Cancer Patients: The M.D. Anderson Symptom Inventory. Cancer, 89, 1634-1646.
https://doi.org/10.1002/1097-0142(20001001)89:7<1634::AID-CNCR29>3.0.CO;2-V
|
[32]
|
Kohli, S., Griggs, J.J., Roscoe, J.A., et al. (2007) Self-Reported Cognitive Impairment in Patients with Cancer. Journal of Oncology Practice, 3, 54-59.
https://doi.org/10.1200/JOP.0722001
|
[33]
|
Tager, F.A., McKinley, P.S., Schnabel, F.R., et al. (2010) The Cognitive Effects of Chemotherapy in Post-Menopausal Breast Cancer Patients: A Controlled Longitudinal Study. Breast Cancer Research and Treatment, 123, 25-34.
https://doi.org/10.1007/s10549-009-0606-8
|
[34]
|
Pullens, M.J., De Vries, J. and Roukema, J.A. (2010) Subjective Cognitive Dysfunction in Breast Cancer Patients: A Systematic Review. Psychooncology, 19, 1127-1138. https://doi.org/10.1002/pon.1673
|
[35]
|
Vardy, J. and Tannock, I. (2007) Cognitive Function after Chemotherapy in Adults with Solid Tumours. Critical Reviews in Oncology/Hematology, 63, 183-202.
https://doi.org/10.1016/j.critrevonc.2007.06.001
|
[36]
|
van der Wall, E., Nooijen, W.J., Baars, J.W., Holtkamp, N.J., Schorangel, J.H., Richel, D.J., et al. (1995) High-Dose Carboplatin, Thiotepa and Cyclophosphamide (CTC) with Peripheral Blood Stem Cell Support in the Adjuvant Therapy of High-Risk Breast Cancer: A Practical Approach. British Journal of Cancer, 71, 857-862.
|
[37]
|
Shilling, V., Jenkins, V. and Trapala, I.S. (2006) The (Mis)classification of Chemo-Fog-Methodological Inconsistencies in the Investigation of Cognitive Impairment after Chemotherapy. Breast Cancer Research and Treatment, 95, 125-129.
https://doi.org/10.1007/s10549-005-9055-1
|
[38]
|
Jansen, C.E., Miaskowski, C.A., Dodd, M.J. and Dowling, G.A. (2007) A Meta-Analysis of the Sensitivity of Various Neuropsychological Tests Used to Detect Chemotherapy-Induced Cognitive Impairment in Patients with Breast Cancer. Oncology Nursing Forum, 34, 997-1005. https://doi.org/10.1188/07.ONF.997-1005
|
[39]
|
Wefel, J.S., Vardy, J., Ahles, T., et al. (2011) International Cognition and Cancer Task Force Recommendations to Harmonise Studies of Cognitive Function in Patients with Cancer. The Lancet Oncology, 12, 703-708.
https://doi.org/10.1016/S1470-2045(10)70294-1
|
[40]
|
Jim, H.S., Phillips, K.M., Chair, S., et al. (2012) Meta-Analysis of Cognitive Functioning in Breast Cancer Survivors Previously Treated with Standard-Dose Chemotherapy. Journal of Clinical Oncology, 30, 3578-3587.
https://doi.org/10.1200/JCO.2011.39.5640
|
[41]
|
Bernstein, L.J., McCreath, G.A., Komeylian, Z., et al. (2017) Cognitive Impairment in Breast Cancer Survivors Treated with Chemotherapy Depends on Control Group Type and Cognitive Domains Assessed: A Multilevel Meta-Analysis. Neuroscience & Biobehavioral Reviews, 83, 417-428.
https://doi.org/10.1016/j.neubiorev.2017.10.028
|
[42]
|
Collins, B., MacKenzie, J., Tasca, G.A., et al. (2013) Cognitive Effects of Chemotherapy in Breast Cancer Patients: A Dose-Response Study. Psychooncology, 22, 1517-1527. https://doi.org/10.1002/pon.3163
|
[43]
|
Quach, C., Hommet, C., Mondon, K., Lauvin, M.A., Cazals, X. and Cottier, J.P. (2014) Early-Onset Dementias: Specific Etiologies and Contribution of MRI. Diagnostic and Interventional Imaging, 95, 377-398. https://doi.org/10.1016/j.diii.2013.07.009
|
[44]
|
Li, M.C.K. (2018) Longitudinal Assessment of Chemotherapy-Induced Changes in Brain and Cognitive Functioning: A Systematic Review. Neuroscience & Biobehavioral Reviews, 92, 304-317. https://doi.org/10.1016/j.neubiorev.2018.05.019
|
[45]
|
McDonald, B.C., Conroy, S.K., Smith, D.J., et al. (2013) Frontal Gray Matter Reduction after Breast Cancer Chemotherapy and Association with Executive Symptoms: A Replication and Extension Study. Brain, Behavior, and Immunity, 30, S117-S125.
https://doi.org/10.1016/j.bbi.2012.05.007
|
[46]
|
Lepage, C., Smith, A.M., Moreau, J., et al. (2014) A Prospective Study of Grey Matter and Cognitive Function Alterations in Chemotherapy-Treated Breast Cancer Patients. Springerplus, 19, 444. https://doi.org/10.1186/2193-1801-3-444
|
[47]
|
Amidi, A., Agerbaek, M., Wu, L.M., et al. (2017) Changes in Cognitive Functions and Cerebral Grey Matter and Their Associations with Inflammatory Markers, Endocrine Markers, and APOE Genotypes in Testicular Cancer Patients Undergoing Treatment. Brain Imaging and Behavior, 11, 769-783.
https://doi.org/10.1007/s11682-016-9552-3
|
[48]
|
Matsos, A., Loomes, M., Zhou, I., et al. (2017) Chemotherapy-Induced Cognitive Impairments: White Matter Pathologies. Cancer Treatment Reviews, 61, 6-14.
https://doi.org/10.1016/j.ctrv.2017.09.010
|
[49]
|
Abraham, J., Haut, M.W., Moran, M.T., et al. (2008) Adjuvant Chemotherapy for Breast Cancer: Effects on Cerebral White Matter Seen in Diffusion Tensor Imaging. Clinical Breast Cancer, 8, 88-91. https://doi.org/10.3816/CBC.2008.n.007
|
[50]
|
Choi, S.M., Lee, S.H., Yang, Y.S., et al. (2001) 5-Fluorouracil-Induced Leukoencephalopathy in Patients with Breast Cancer. Journal of Korean Medical Science, 16, 328-334. https://doi.org/10.3346/jkms.2001.16.3.328
|
[51]
|
Deprez, S., Amant, F., Smeets, A., et al. (2012) Longitudinal Assessment of Chemotherapy-Induced Structural Changes in Cerebral White Matter and Its Correlation with Impaired Cognitive Functioning. Journal of Clinical Oncology, 30, 274-281.
https://doi.org/10.1200/JCO.2011.36.8571
|
[52]
|
Nudelman, K.N., Wang, Y., McDonald, B.C., et al. (2014) Altered Cerebral Blood Flow One Month after Systemic Chemotherapy for Breast Cancer: A Prospective Study Using Pulsed Arterial Spin Labeling MRI Perfusion. PLoS ONE, 9, e96713.
https://doi.org/10.1371/journal.pone.0096713
|
[53]
|
Chen, X., He, X., Tao, L., et al. (2017) The Attention Network Changes in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy: Evidence from an Arterial Spin Labeling Perfusion Study. Scientific Reports, 17, Article No. 42684.
https://doi.org/10.1038/srep42684
|
[54]
|
Miao, H., Li, J., Hu, S., et al. (2016) Long-Term Cognitive Impairment of Breast Cancer Patients after Chemotherapy: A Functional MRI Study. European Journal of Radiology, 85, 1053-1057. https://doi.org/10.1016/j.ejrad.2016.03.011
|
[55]
|
Amidi, A., Hosseini, S.M.H., Leemans, A., et al. (2017) Changes in Brain Structural Networks and Cognitive Functions in Testicular Cancer Patients Receiving Cisplatin-Based Chemotherapy. Journal of the National Cancer Institute, 109, djx085.
https://doi.org/10.1093/jnci/djx085
|
[56]
|
Bassett, D.S. and Bullmore, E. (2006) Small-World Brain Networks. Neuroscientist, 12, 512-523. https://doi.org/10.1177/1073858406293182
|
[57]
|
Hutchinson, A.D., Hosking, J.R., Kichenadasse, et al. (2012) Objective and Subjective Cognitive Impairment Following Chemotherapy for Cancer: A Systematic Review. Cancer Treatment Reviews, 38, 926-934.
https://doi.org/10.1016/j.ctrv.2012.05.002
|
[58]
|
Srisurapanont, M., Suttajit, S., Eurviriyanukul, K., et al. (2017) Discrepancy between Objective and Subjective Cognition in Adults with Major Depressive Disorder. Scientific Reports, 7, Article No. 3901. https://doi.org/10.1038/s41598-017-04353-w
|
[59]
|
Maor, Y., Olmer, L. and Mozes, B. (2001) The Relation between Objective and Subjective Impairment in Cognitive Function among Multiple Sclerosis Patients—The Role of Depression. Multiple Sclerosis, 7, 131-135.
https://doi.org/10.1177/135245850100700209
|
[60]
|
Thames, A.D., et al. (2011) Depression, Cognition, and Self-Appraisal of Functional Abilities in HIV: An Examination of Subjective Appraisal versus Objective Performance. The Clinical Neuropsychologist, 25, 224-243.
https://doi.org/10.1080/13854046.2010.539577
|
[61]
|
Yoon, B.Y., Lee, J.-H. and Shin, S.Y. (2017) Discrepancy between Subjective and Objective Measures of Cognitive Impairment in Patients with Rheumatoid Arthritis. Rheumatology International, 37, 1635-1641.
https://doi.org/10.1007/s00296-017-3806-2
|
[62]
|
Rabin, L.A., Smart, C.M. and Amariglio, R.E. (2017) Subjective Cognitive Decline in Preclinical Alzheimer’s Disease. Annual Review of Clinical Psychology, 13, 369-396.
https://doi.org/10.1146/annurev-clinpsy-032816-045136
|
[63]
|
Dufouil, C., Fuhrer, R. and Alperovitch, A. (2005) Subjective Cognitive Complaints and Cognitive Decline: Consequence or Predictor? The Epidemiology of Vascular Aging Study, 53, 616-621. https://doi.org/10.1111/j.1532-5415.2005.53209.x
|
[64]
|
Henderson, F.M., Cross, A.J. and Baraniak, A.R. (2019) A New Normal with Chemobrain: Experiences of the Impact of Chemotherapy-Related Cognitive Deficits in Long-Term Breast Cancer Survivors. Health Psychology Open, 6.
https://doi.org/10.1177/2055102919832234
|
[65]
|
Boykoff, N., Moieni, M. and Subramanian, S.K. (2009) Confronting Chemobrain: An In-Depth Look at Survivors’ Reports of Impact on Work, Social Networks, and Health Care Response. Journal of Cancer Survivorship, 3, 223-232.
https://doi.org/10.1007/s11764-009-0098-x
|
[66]
|
Bolton, G.I.A. (2018) Women’s Experiences of Cancer-Related Cognitive Impairment, Its Impact on Daily Life and Care Received for It Following Treatment for Breast Cancer. Psychology, Health & Medicine, 23, 1261-1274.
https://doi.org/10.1080/13548506.2018.1500023
|
[67]
|
Mandelblatt, J.S., Jacobsen, P.B. and Ahles, T. (2014) Cognitive Effects of Cancer Systemic Therapy: Implications for the Care of Older Patients and Survivors. Journal of Clinical Oncology, 32, 2617-2626. https://doi.org/10.1200/JCO.2014.55.1259
|
[68]
|
Sternberg, S.A., Schwartz, A.W., Karunananthan, S., et al. (2011) The Identification of Frailty: A Systematic Literature Review. Journal of the American Geriatrics Society, 59, 2129-2138. https://doi.org/10.1111/j.1532-5415.2011.03597.x
|
[69]
|
Ness, K.K., Krull, K.R., Jones, K.E., et al. (2013) Physiologic Frailty as a Sign of Accelerated Aging among Adult Survivors of Childhood Cancer: A Report from the St Jude Lifetime Cohort Study. Journal of Clinical Oncology, 31, 4496-4503.
https://doi.org/10.1200/JCO.2013.52.2268
|
[70]
|
Maccormick, R.E. (2006) Possible Acceleration of Aging by Adjuvant Chemotherapy: A Cause of Early Onset Frailty? Medical Hypotheses, 67, 212-215.
https://doi.org/10.1016/j.mehy.2006.01.045
|
[71]
|
Sanoff, H.K., Deal, A.M., Krishnamurthy, J., et al. (2014) Effect of Cytotoxic Chemotherapy on Markers of Molecular Age in Patients with Breast Cancer. Journal of the National Cancer Institute, 106, dju057. https://doi.org/10.1093/jnci/dju057
|
[72]
|
Chiang, A.C.A., Huo, X., Kavelaars, A., et al. (2019) Chemotherapy Accelerates Age-Related Development of Tauopathy and Results in Loss of Synaptic Integrity and Cognitive Impairment. Brain, Behavior, and Immunity, 79, 319-325.
https://doi.org/10.1016/j.bbi.2019.04.005
|
[73]
|
Carroll, J.E., Van Dyk, K., Bower, J.E., et al. (2019) Cognitive Performance in Survivors of Breast Cancer and Markers of Biological Aging. Cancer, 125, 298-306.
https://doi.org/10.1002/cncr.31777
|
[74]
|
Wang, X.M., Walitt, B., Saligan, L., et al. (2015) Chemobrain: A Critical Review and Causal Hypothesis of Link between Cytokines and Epigenetic Reprogramming Associated with Chemotherapy. Cytokine, 72, 86-96.
https://doi.org/10.1016/j.cyto.2014.12.006
|
[75]
|
Lyon, D.E., Cohen, R., Chen, H., et al. (2016) Relationship of Systemic Cytokine Concentrations to Cognitive Function over Two Years in Women with Early Stage Breast Cancer. Journal of Neuroimmunology, 301, 74-82.
https://doi.org/10.1016/j.jneuroim.2016.11.002
|
[76]
|
Chae, J.W., Ng, T., Yeo, H.L., et al. (2016) Impact of TNF-α (rs1800629) and IL-6 (rs1800795) Polymorphisms on Cognitive Impairment in Asian Breast Cancer Patients. PLoS ONE, 11, e0164204. https://doi.org/10.1371/journal.pone.0164204
|
[77]
|
Kesler, S., Janelsins, M., Koovakkattu, D., et al. (2013) Reduced Hippocampal Volume and Verbal Memory Performance Associated with Interleukin-6 and Tumor Necrosis Factor-Alpha Levels in Chemotherapy-Treated Breast Cancer Survivors. Brain, Behavior, and Immunity, 30, 109-116.
https://doi.org/10.1016/j.bbi.2012.05.017
|
[78]
|
Shi, D.D., Huang, Y.H., Lai, C.S.W., et al. (2019) Chemotherapy-Induced Cognitive Impairment Is Associated with Cytokine Dysregulation and Disruptions in Neuroplasticity. Molecular Neurobiology, 56, 2234-2243.
https://doi.org/10.1007/s12035-018-1224-4
|
[79]
|
Pizzino, G., Irrera, N., Cucinotta, M., et al. (2017) Oxidative Stress: Harms and Benefits for Human Health. Oxidative Medicine and Cellular Longevity, 2017, Article ID: 8416763. https://doi.org/10.1155/2017/8416763
|
[80]
|
Huang, W.J., Zhang, X. and Chen, W.W. (2016) Role of Oxidative Stress in Alzheimer’s Disease. Biomedical Reports, 4, 519-522. https://doi.org/10.3892/br.2016.630
|
[81]
|
Butterfield, D.A. (2014) The 2013 Discovery Award from the Society for Free Radical Biology and Medicine: Selected Discoveries from the Butterfield Laboratory of Oxidative Stress and Its Sequelae in Brain in Cognitive Disorders Exemplified by Alzheimer Disease and Chemotherapy Induced Cognitive Impairment. Free Radical Biology & Medicine, 157-174. https://doi.org/10.1016/j.freeradbiomed.2014.06.006
|
[82]
|
Chen, Y., Jungsuwadee, P., Vore, M., et al. (2007) Collateral Damage in Cancer Chemotherapy: Oxidative Stress in Nontargeted Tissues. Molecular Interventions, 7, 147-156. https://doi.org/10.1124/mi.7.3.6
|
[83]
|
Chatterjee, K., Zhang, J.Q., Honbo, N., et al. (2010) Doxorubicin Cardiomyopathy. Cardiology, 115, 115-162. https://doi.org/10.1159/000265166
|
[84]
|
Joshi, G., Sultana, R., Tangpong, J., et al. (2005) Free Radical Mediated Oxidative Stress and Toxic Side Effects in Brain Induced by the Anti Cancer Drug Adriamycin: Insight into Chemobrain. Free Radical Research, 39, 1147-1154.
https://doi.org/10.1080/10715760500143478
|
[85]
|
Tangpong, J., Cole, M.P., Sultana, R., et al. (2006) Adriamycin-Induced, TNF-Alpha- Mediated Central Nervous System Toxicity. Neurobiology of Disease, 23, 127-139.
https://doi.org/10.1016/j.nbd.2006.02.013
|
[86]
|
Beckhauser, T.F., Francis-Oliveira, J. and De Pasquale, R. (2016) Reactive Oxygen Species: Physiological and Physiopathological Effects on Synaptic Plasticity. Journal of Experimental Neuroscience, 10, 23-48. https://doi.org/10.4137/JEN.S39887
|
[87]
|
Gaman, A.M., Uzoni, A., Popa-Wagner, A., et al. (2016) The Role of Oxidative Stress in Etiopathogenesis of Chemotherapy Induced Cognitive Impairment (CICI)- “Chemobrain”. Aging and Disease, 7, 307-317.
https://doi.org/10.14336/AD.2015.1022
|
[88]
|
Keeney, J.T.R., Ren, X., Warrier, G., et al. (2018) Doxorubicin-Induced Elevated Oxidative Stress and Neurochemical Alterations in Brain and Cognitive Decline: Protection by MESNA and Insights into Mechanisms of Chemotherapy-Induced Cognitive Impairment (“Chemobrain”). Oncotarget, 9, 30324-30339.
https://doi.org/10.18632/oncotarget.25718
|
[89]
|
Froklage, F.E., Reijneveld, J.C., Heimans, J.J., et al. (2011) Central Neurotoxicity in Cancer Chemotherapy: Pharmacogenetic Insights. Pharmacogenomics, 12, 379-395.
https://doi.org/10.2217/pgs.10.197
|
[90]
|
Ahles, T.A., Saykin, A.J., Noll, W.W., et al. (2003) The Relationship of APOE Genotype to Neuropsychological Performance in Long-Term Cancer Survivors Treated with Standard Dose Chemotherapy. Psychooncology, 12, 612-619.
https://doi.org/10.1002/pon.742
|
[91]
|
Triarico, S., Maurizi, P., Mastrangelo, S., et al. (2019) Improving the Brain Delivery of Chemotherapeutic Drugs in Childhood Brain Tumors. Cancers (Basel), 11, pii: E824. https://doi.org/10.3390/cancers11060824
|
[92]
|
Kwan, P. and Brodie, M.J. (2005) Potential Role of Drug Transporters in the Pathogenesis of Medically Intractable Epilepsy. Epilepsia, 46, 224-235.
https://doi.org/10.1111/j.0013-9580.2005.31904.x
|
[93]
|
Lee, W., Glaeser, H., Smith, L.H., et al. (2005) Polymorphisms in Human Organic Anion-Transporting Polypeptide 1A2 OATP1A2, Implications for Altered Drug Disposition and Central Nervous System Drug Entry. The Journal of Biological Chemistry, 280, 9610-9617. https://doi.org/10.1074/jbc.M411092200
|
[94]
|
Tulsyan, S., Mittal, R.D. and Mittal, B. (2016) The Effect of ABCB1 Polymorphisms on the Outcome of Breast Cancer Treatment. Pharmacogenomics and Personalized Medicine, 27, 47-58. https://doi.org/10.2147/PGPM.S86672
|
[95]
|
Erdilyi, D.J., Kamory, E., Csokay, B., et al. (2008) Synergistic Interaction of ABCB1 and ABCG2 Polymorphisms Predicts the Prevalence of Toxicencephalopathy during Anticancer Chemotherapy. The Pharmacogenomics Journal, 8, 321-327.
https://doi.org/10.1038/sj.tpj.6500480
|
[96]
|
Hodges, L.M., Markova, S.M. and Chinn, L.W. (2011) Very Important Pharmacogene Summary: ABCB1 (MDR1, P-Glycoprotein). Pharmacogenet Genomics, 21, 152-161. https://doi.org/10.1097/FPC.0b013e3283385a1c
|
[97]
|
Steward, K.A., Kennedy, R., Novack, T.A., et al. (2018) The Role of Cognitive Reserve in Recovery from Traumatic Brain Injury. The Journal of Head Trauma Rehabilitation, 33, E18-E27. https://doi.org/10.1097/HTR.0000000000000325
|
[98]
|
Stern, Y. (2006) Cognitive Reserve and Alzheimer Disease. Alzheimer Disease & Associated Disorders, 20, 112-117.
https://doi.org/10.1097/01.wad.0000213815.20177.19
|
[99]
|
Ahles, T., Saykin, A.J., McDonald, B.C., et al. (2010) Longitudinal Assessment of Cognitive Changes Associated with Adjuvant Treatment for Breast Cancer: Impact of Age and Cognitive Reserve. Journal of Clinical Oncology, 28, 4434-4440.
https://doi.org/10.1200/JCO.2009.27.0827
|
[100]
|
Inno, A., Metro, G., Bironzo, P., et al. (2017) Pathogenesis, Clinical Manifestations and Management of Immune Checkpoint Inhibitors Toxicity. Tumori Journal, 103, 405-421. https://doi.org/10.5301/tj.5000625
|
[101]
|
Spain, L., Walls, G., Julve, M., et al. (2017) Neurotoxicity from Immune-Checkpoint Inhibition in the Treatment of Melanoma: A Single Centre Experience and Review of the Literature. Annals of Oncology, 28, 377-385.
|
[102]
|
Voskens, C.J., Goldinger, S.M., Loquai, C., et al. (2013) The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network. PLoS ONE, 8, e53745.
https://doi.org/10.1371/journal.pone.0053745
|
[103]
|
Zimmer, L., Goldinger, S.M., Hofmann, L., et al. (2016) Neurological, Respiratory, Musculoskeletal, Cardiac and Ocular Side-Effects of Anti-PD-1 Therapy. European Journal of Cancer, 60, 210-225. https://doi.org/10.1016/j.ejca.2016.02.024
|
[104]
|
McGinnis, G.J., Friedman, D., Young, K.H., et al. (2017) Neuroinflammatory and Cognitive Consequences of Combined Radiation and Immunotherapy in a Novel Preclinical Model. Oncotarget, 8, 9155-9173.
https://doi.org/10.18632/oncotarget.13551
|
[105]
|
Cuzzubbo, S., Belin, C., Chouahnia, K., et al. (2018) Assessing Cognitive Function in Patients Treated with Immune Checkpoint Inhibitors: A Feasibility Study. Psychooncology, 27, 1861-1864. https://doi.org/10.1002/pon.4725
|
[106]
|
Zhou, W., Kavelaars, A. and Heijnen, C.J. (2016) Metformin Prevents Cisplatin-Induced Cognitive Impairment and Brain Damage in Mice. PLoS ONE, 11, e0151890.
https://doi.org/10.1371/journal.pone.0151890
|
[107]
|
Chiu, G.S., Boukelmoune, N., Chiang, A.C.A., et al. (2018) Nasal Administration of Mesenchymal Stem Cells Restores Cisplatin-Induced Cognitive Impairment and Brain Damage in Mice. Oncotarget, 9, 35581-35597.
https://doi.org/10.18632/oncotarget.26272
|
[108]
|
Philpot, R.M., Ficken, M., Johns, B.E., et al. (2019) Spatial Memory Deficits in Mice Induced by Chemotherapeutic Agents Are Prevented by Acetylcholinesterase Inhibitors. Cancer Chemotherapy and Pharmacology, 84, 579-589.
https://doi.org/10.1007/s00280-019-03881-8
|
[109]
|
Birks, J.S. and Harvey, R.J. (2018) Donepezil for Dementia Due to Alzheimer’s Disease. Cochrane Database of Systematic Reviews, No. 6, CD001190.
https://doi.org/10.1002/14651858.CD001190.pub3
|
[110]
|
Rapp, S.R., et al. (2015) Donepezil for Irradiated Brain Tumor Survivors: A Phase III Randomized Placebo-Controlled Clinical Trial. JCO, 33, 1653-1659.
https://doi.org/10.1200/JCO.2014.58.4508
|
[111]
|
Lawrence, J.A., et al. (2016) A Study of Donepezil in Female Breast Cancer Survivors with Self-Reported Cognitive Dysfunction 1 to 5 Years Following Adjuvant Chemotherapy. Journal of Cancer Survivorship, 10, 176-184.
https://doi.org/10.1007/s11764-015-0463-x
|
[112]
|
Kohli, S., et al. (2009) The Effect of Modafinil on Cognitive Function in Breast Cancer Survivors. Cancer, 115, 2605-2616. https://doi.org/10.1002/cncr.24287
|
[113]
|
Lundorff, L., Jonsson, B. and Sjogren, P. (2009) Modafinil for Attentional and Psychomotor Dysfunction in Advanced Cancer: A Double-Blind, Randomised, Cross- Over Trial. Palliative Medicine, 23, 731-738.
https://doi.org/10.1177/0269216309106872
|
[114]
|
Blackhall, L., Petroni, G., Shu, J., Baum, L. and Farace, E. (2009) A Pilot Study Evaluating the Safety and Efficacy of Modafinil for Cancer-Related Fatigue. Journal of Palliative Medicine, 12, 433-439. https://doi.org/10.1089/jpm.2008.0230
|
[115]
|
Berenson, J.R., et al. (2015) A Phase 3 Trial of Armodafinil for the Treatment of Cancer-Related Fatigue for Patients with Multiple Myeloma. Support Care Cancer, 23, 1503-1512. https://doi.org/10.1007/s00520-014-2486-7
|
[116]
|
Kredlow, M.A., Keshishian, A., Oppenheimer, S. and Otto, M.W. (2019) The Efficacy of Modafinil as a Cognitive Enhancer. Journal of Clinical Psychopharmacology, 39, 455-461. https://doi.org/10.1097/JCP.0000000000001085
|
[117]
|
Escalante, C.P., et al. (2014) A Randomized, Double-Blind, 2-Period, Placebo-Controlled Crossover Trial of a Sustained-Release Methylphenidate in the Treatment of Fatigue in Cancer Patients. The Cancer Journal, 20, 8-14.
https://doi.org/10.1097/PPO.0000000000000018
|
[118]
|
Cifu, G., Power, M.C., Shomstein, S., et al. (2018) Mindfulness-Based Interventions and Cognitive Function among Breast Cancer Survivors: A Systematic Review. BMC Cancer, 18, 1163. https://doi.org/10.1186/s12885-018-5065-3
|
[119]
|
Reich, R.R., et al. (2017) Mindfulness-Based Stress Reduction in Post-Treatment Breast Cancer Patients: Immediate and Sustained Effects across Multiple Symptom Clusters. Journal of Pain and Symptom Management, 53, 85-95.
https://doi.org/10.1016/j.jpainsymman.2016.08.005
|
[120]
|
Dobos, G., et al. (2015) Integrating Mindfulness in Supportive Cancer Care: A Cohort Study on a Mindfulness-Based Day Care Clinic for Cancer Survivors. Support Care Cancer, 23, 2945-2955. https://doi.org/10.1007/s00520-015-2660-6
|
[121]
|
Ferguson, R.J., Ahles, T.A., Saykin, A.J., et al. (2007) Cognitive-Behavioral Management of Chemotherapy-Related Cognitive Change. Psychooncology, 16, 772-777.
https://doi.org/10.1002/pon.1133
|
[122]
|
Fernandes, H.A., Richard, N.M. and Edelstein, K. (2019) Cognitive Rehabilitation for Cancer-Related Cognitive Dysfunction: A Systematic Review. Support Care Cancer, 27, 3253-3279. https://doi.org/10.1007/s00520-019-04866-2
|
[123]
|
Park, H.S., Kim, C.J., Kwak, H.B., et al. (2018) Physical Exercise Prevents Cognitive Impairment by Enhancing Hippocampal Neuroplasticity and Mitochondrial Function in Doxorubicin-Induced Chemobrain. Neuropharmacology, 133, 451-461.
https://doi.org/10.1016/j.neuropharm.2018.02.013
|
[124]
|
Oberste, M., Schaffrath, N., Schmidt, K., et al. (2018) Protocol for the “Chemobrain in Motion Study”. CIM Study, a Randomized Placebo-Controlled Trial of the Impact of a High-Intensity Interval Endurance Training on Cancer Related Cognitive Impairments in Women with Breast Cancer Receiving First-Line Chemotherapy. BMC Cancer, 18, 1071. https://doi.org/10.1186/s12885-018-4992-3
|
[125]
|
Zimmer, P., Oberste, M., Bloch, W., et al. (2016) Impact of Aerobic Exercise Training during Chemotherapy on Cancer Related Cognitive Impairments in Patients Suffering from Acute Myeloid Leukemia or Myelodysplastic Syndrome—Study Protocol of a Randomized Placebo-Controlled Trial. Contemporary Clinical Trials, 49, 1-5. https://doi.org/10.1016/j.cct.2016.05.007
|